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Abstract
Background: Research on olfactory G-protein coupled receptors (GPCRs) has been severely
impeded by poor functional expression in heterologous systems. Previously, we demonstrated that
inefficient olfactory receptor (OR) expression at the plasma membrane is attributable, in part, to
degradation of endoplasmic reticulum (ER)-retained ORs by the ubiquitin-proteasome system and
sequestration of ORs in ER aggregates that are degraded by autophagy. Thus, experiments were
performed to test the hypothesis that attenuation of ER degradation improves OR functional
expression in heterologous cells.
Results: To develop means to increase the functional expression of ORs, we devised an approach
to measure activation of the mOREG OR (Unigene # Mm.196680; Olfr73) through coupling to an
olfactory cyclic nucleotide-gated cation channel (CNG). This system, which utilizes signal
transduction machinery coupled to OR activation in native olfactory sensory neurons, was used to
demonstrate that degradation, both by the ubiquitin-proteasome system and autophagy, limits
mOREG functional expression. The stimulatory effects of proteasome and autophagy inhibitors on
mOREG function required export from the ER and trafficking through the biosynthetic pathway.
Conclusions:  These findings demonstrate that poor functional expression of mOREG in
heterologous cells is improved by blocking proteolysis. Inhibition of ER degradation may improve
the function of other ORs and assist future efforts to elucidate the molecular basis of odor
discrimination.
Background
The sense of smell originates in the olfactory epithelium
when olfactory receptors (ORs), members of the seven
transmembrane domain G-protein coupled receptor
(GPCR) superfamily, bind odorant ligands [1,2]. Despite
identification of the first constituents of the ~1000 mem-
ber OR superfamily over a decade ago, efforts to uncover
the molecular basis of odor discrimination have been
severely limited by the inability to efficiently express ORs
at the plasma membrane in heterologous expression sys-
tems [2-6].
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Recently, we elucidated three specific cellular mechanisms
responsible for inefficient OR trafficking to the plasma
membrane: ORs are retained within the endoplasmic
reticulum (ER) due to inefficient folding and poor cou-
pling to ER export machinery, degraded via the ubiquitin-
proteasome system, and sequestered in ER aggregates that
are degraded by autophagy [7]. Thus, we have a clearer
understanding of the problems associated with OR
expression in heterologous cells.
To develop rationale means to improve the functional
expression of ORs, an approach was devised to quantitate
activation of the mouse mOREG OR (Unigene #
Mm.196680; Olfr73), which recognizes the odorant eug-
enol (spicy, cinnamon-like odor) [8], following coupling
to an olfactory cyclic nucleotide-gated cation channel
(CNG) [9]. Using this assay, we show that degradation by
both the ubiquitin-proteasome system and autophagy
limits mOREG functional expression. Our results demon-
strate for the first time that inhibition of proteolysis can
positively modulate OR function.
Results and discussion
Functional expression of mOREG using a CNG-based 
assay
A cell-based approach was developed to measure func-
tional expression of mOREG in heterologous cells. This
system was designed to mimic the signal transduction
events involved in OR activation in the olfactory epithe-
lium and utilizes CNG as a cAMP biosensor [10,11]. In
olfactory sensory neurons, odorant binding to ORs initi-
ates a signaling cascade involving the heterotrimeric G
protein Golf, adenylate cyclase III, and an olfactory CNG,
leading ultimately to the sensation of smell [1,12].
Accordingly, we transiently co-expressed mOREG, as an
N-terminal fusion protein with the first 20 amino acids of
rhodopsin (Rho20-mOREG), with untagged olfactory
CNG subunits in HEK293 cells that endogenously express
both the heterotrimeric G protein Gs, a functional homo-
logue of Golf [13,14], and adenylate cyclase III [15]. The
Rho tag has been shown to facilitate chemosensory GPCR
functional expression [8,16,17], possibly by enhancing
translocation into the ER during protein synthesis. In this
system, odorant binding to Rho-mOREG, which couples
to endogenous Gs and elicits increases in the second mes-
senger cAMP in HEK cells [8,18,19], leads to the opening
of CNG and the influx of calcium from the extracellular
medium. Thus, Rho-mOREG function can be directly cor-
related with cellular calcium levels.
Responses to eugenol, a ligand for mOREG, were detected
in cells co-expressing Rho-mOREG and CNG (Fig. 1A and
1B) but not in cells expressing vector only, Rho-mOREG
only, or CNG only (Fig. 1B). Eugenol activation of Rho-
mOREG became evident at 20 sec and increased to a max-
imal level at 50 sec following odorant application. The
EC50 for eugenol (20.8 +/- 3.4 uM) closely approximated
published values (35 uM and 46 uM), thereby validating
the utility of our approach [8,19]. Rho-mOREG activation
was specific for eugenol as no response was observed
when cells were challenged with the control odorants hep-
tanal and octanal, which activate the I7 OR (Fig. 1B)
[4,16,20]. Collectively, these data demonstrate that Rho-
mOREG can functionally couple to CNG in heterologous
cells following odorant stimulation.
ER degradation limits mOREG functional expression
Previously, we demonstrated that ORs are inefficiently
expressed at the plasma membrane of heterologous cells
due, in part, to degradation of ER-retained ORs by the
ubiquitin-proteasome system and sequestration of ORs in
ER aggregates that are degraded by autophagy [7]. Specif-
ically, inhibition of the proteasome using MG-132 or
inhibition of autophagy using 3-methyladenine (3-MA)
enhanced Rho-mOREG protein expression 2 to 3-fold by
biochemical and cellular analyses [7]. Therefore, experi-
ments were performed to test the hypothesis that ER deg-
radation limits OR functional expression. These studies
used cells stably expressing CNG and transiently express-
ing Rho-mOREG to achieve more robust responses. As
shown in Figure 2, treatment of cells with 3-MA, a specific
inhibitor of autophagy that blocks sequestration of mate-
rial into autophagosomes [21], enhanced Rho-mOREG
activation by eugenol (compare Fig. 2A and 2B). Similar
results were obtained when cells were treated with MG-
132 (compare Fig. 2A and 2C) or epoxomicin (data not
shown), a specific inhibitor of the proteasome [22].
Autophagy and proteasome inhibitors increased Rho-
mOREG functional expression 2 to 3-fold in the linear
range of eugenol dose response curves (Fig. 2D and 2F).
Importantly, 3-MA and MG-132 specifically promoted
Rho-mOREG function, since responses of the β-adrener-
gic receptor (β-AR), a GPCR that utilizes the same signal
transduction machinery as Rho-mOREG (GPCR-Gs-ade-
nylate cyclase) [14], following isoproterenol challenge
were unaffected (Fig. 2E and 2G). Thus, degradation
inhibitors were not modulating the function or trafficking
of elements of the signal transduction machinery, includ-
ing CNG, coupled to Rho-mOREG. Collectively, these
data suggest that ER degradation, by autophagy and the
ubiquitin-proteasome system, limits Rho-mOREG func-
tional expression.
To determine if increased functional expression of Rho-
mOREG following inhibition of ER degradation was
attributable to use of an OR fusion protein, we examined
the effect of autophagy and proteasome inhibitors on
mOREG lacking the Rho tag. Although eugenol activation
of Rho-mOREG (EC50  = 17.1 +/- 3.0 uM; maximum
number of responding cells at 300 uM eugenol = 214 +/-BMC Cell Biology 2004, 5:34 http://www.biomedcentral.com/1471-2121/5/34
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10) was more robust than untagged mOREG (EC50 = 36.5
+/- 12.9 uM; maximum number of responding cells at 300
uM eugenol = 48 +/- 5; p < 0.05 compared to Rho-
mOREG for both EC50 and maximal number of respond-
ing cells), likely due to an established role of the Rho tag
in facilitating chemosensory GPCR functional expression
Functional expression of Rho-mOREG using a CNG-based assay Figure 1
Functional expression of Rho-mOREG using a CNG-based assay. (A) HEK293 cells transiently transfected with Rho-
mOREG and CNG were assayed for increases in intracellular calcium in response to 100 uM eugenol. Images contain ~2000 
confluent cells and represent responses at the indicated times following odorant stimulation. Scale bar is 300 um. Responses 
were observed in ~10% of total cells or ~20% of transfected cells (~50% transfection efficiency). (B) Quantitation of cells 
expressing vector only (a), Rho-mOREG only (b), CNG only (c), Rho-mOREG and CNG (d and e) following stimulation with 
100 uM eugenol (a-d) or 100 uM heptanal plus 100 uM octanal (e). * p < 0.001 compared to cells expressing vector only (a).BMC Cell Biology 2004, 5:34 http://www.biomedcentral.com/1471-2121/5/34
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ER degradation limits Rho-mOREG functional expression Figure 2
ER degradation limits Rho-mOREG functional expression. CNG cells transiently transfected with Rho-mOREG were 
assayed for increases in intracellular calcium in response to 10 uM eugenol following treatment with vehicle (control, 0.1% 
DMSO; A), 10 mM 3-MA (B) or 50 uM MG-132 (C) for 4 h. Images contain ~750–1000 confluent cells and represent responses 
60 sec following odorant stimulation. Scale bar is 150 um. Dose-response curves were determined for eugenol (300 nM to 300 
uM; D and F) or isoproterenol (100 pM to 100 nM; E and G) in cells treated with vehicle (control), 10 mM 3-MA (D and E) or 
50 uM MG-132 (F and G) for 4 h. ~20–25% of total cells or ~40–50% of transfected cells (~50% transfection efficiency) 
responded to 100 uM eugenol under control conditions. Note that degradation inhibitors specifically increased Rho-mOREG 
functional responses and had no effect on β-AR function. The EC50 value for eugenol was larger for control (17.1 +/- 3.0 uM) 
compared to 3-MA (10.8 +/- 2.6 uM) and MG-132 (8.1 +/- 2.6 uM) treatments, but these differences did not achieve statistical 
significance. The EC50 values for isoproterenol for control (3.7 +/- 1.0 nM), 3-MA (4.2 +/- 2.5 nM), and MG-132 (2.6 +/- 0.9 nM) 
treatments were not significantly different.BMC Cell Biology 2004, 5:34 http://www.biomedcentral.com/1471-2121/5/34
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[8,16,17], MG-132 and 3-MA increased untagged mOREG
functional expression 2 to 3-fold (Fig. 3), similar to the
magnitude observed with Rho-mOREG (Fig. 2). Thus,
inhibition of ER degradation increased Rho-mOREG and
untagged mOREG functional expression, demonstrating
that observed effects were not attributable to use of a non-
native OR fusion protein.
Two seemingly independent mechanisms degrade ORs
retained in the ER. First, OR aggregates sequestered in ER
subdomains are targeted to lysosomes for degradation by
autophagy, and second, misfolded ORs are covalently
modified by polyubiquitination and degraded by the pro-
teasome [7]. To determine if simultaneous inhibition of
autophagy and the ubiquitin-proteasome system pro-
duced additive effects on Rho-mOREG function, we co-
treated cells with 3-MA and MG-132. As shown in Figure
4, Rho-mOREG function, measured using 10 uM eugenol,
a non-saturating concentration near the EC50 value, was
equivalent in cells treated with 3-MA alone, MG-132
alone, or 3-MA plus MG-132.
The non-additive effects of 3-MA and MG-132 on Rho-
mOREG function suggest one of the following two non-
mutually exclusive scenarios: first, OR degradation by
autophagy may be linked to OR degradation by the ubiq-
uitin-proteasome system, by a poorly defined mechanism
as suggested for other aggregation prone proteins [23-25];
second, in addition to ER degradation, an additional
step(s) downstream of proteolysis may limit Rho-mOREG
functional expression in heterologous cells. A recent pre-
liminary report described specialized accessory proteins
that increase OR surface expression and function [26].
These proteins could serve as chaperones to package OR
cargo into COPII vesicles for export from the ER and/or
couple ORs to requisite signal transduction machinery at
the plasma membrane, steps that are both downstream of
ER degradation. In the absence of necessary accessory pro-
teins, functional expression may not exceed a certain level
regardless of the quantity of OR that is diverted from the
degradative pathways by autophagy and ubiquitin-protea-
some inhibitors. The existence of multiple steps limiting
OR functional expression in heterologous cells is further
supported by our findings that the function of mOREG,
lacking the Rho tag, is less robust than Rho-mOREG. Since
the Rho tag may facilitate translocation into the ER during
protein synthesis [8,16,17], ER translocation could com-
prise an additional limiting step, upstream of ER degrada-
tion, for OR functional expression.
ER export and trafficking through the Golgi apparatus are 
necessary for Rho-mOREG functional expression
Inhibition of ER degradation events could permit a pool
of Rho-mOREG to achieve an ER export competent con-
ER degradation limits untagged mOREG functional  expression Figure 3
ER degradation limits untagged mOREG functional 
expression. CNG cells transiently transfected with 
untagged mOREG were assayed for increases in intracellular 
calcium in response to increasing concentrations of eugenol 
(from 3 uM to 1000 uM) following treatment with vehicle 
(control), 10 mM 3-MA, or 50 uM MG-132 for 4 h. The EC50 
values for eugenol for control (36.5 +/- 12.9 uM), 3-MA (42.6 
+/- 6.5 uM), and MG-132 (36.4 +/- 7.5 uM) treatments were 
not significantly different. CNG cells transfected with vector 
only (pUC18) and treated with vehicle, 3-MA, or MG-132 did 
not respond to 1000 uM eugenol.
Simultaneous inhibition of autophagy and the proteasome  does not produce additive Rho-mOREG functional responses Figure 4
Simultaneous inhibition of autophagy and the protea-
some does not produce additive Rho-mOREG func-
tional responses. CNG cells transiently transfected with 
Rho-mOREG were assayed for increases in intracellular cal-
cium in response to 10 uM eugenol following treatment with 
vehicle (control), 10 mM 3-MA, 50 uM MG-132, or 10 mM 3-
MA plus 50 uM MG-132 for 4 h. Individual or combined 
treatment with degradation inhibitors yielded similar levels of 
Rho-mOREG activity. * p < 0.001 compared to cells treated 
with vehicle.BMC Cell Biology 2004, 5:34 http://www.biomedcentral.com/1471-2121/5/34
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formation and traffic through the Golgi apparatus to the
plasma membrane. However, using surface biotinylation,
surface immunofluorescence microscopy, flow cytometry,
and glycosidase digestion assays, we were unable to dem-
onstrate convincing Rho-mOREG surface expression or
visualize a pool of Rho-mOREG containing endoglycosi-
dase H-resistant carbohydrate modifications indicative of
transit through the Golgi apparatus following treatment
with ER degradation inhibitors (ML and BDM unpub-
lished observations). These results suggested that either a
small pool of properly folded Rho-mOREG was expressed
at the plasma membrane in quantities below the
threshold of the cell biological techniques employed to
visualize the receptor, or that a pool of intracellular Rho-
mOREG comprised the functionally responsive popula-
tion in calcium imaging experiments. Notably, numerous
studies have documented the functional expression of
GPCRs and requisite signal transduction machinery in
intracellular compartments, including ER membranes
[27-29].
To differentiate between these two possibilities, we
adopted a pharmacological approach to selectively and
independently block trafficking from compartments in
the early secretory pathway, specifically the ER and Golgi
apparatus. If inhibition of ER degradation does not
increase Rho-mOREG activity under conditions that block
export from ER and Golgi compartments, the functionally
responsive Rho-mOREG population is likely derived from
an internal pool that is required to traffic to the plasma
membrane to function. Conversely, if inhibition of ER
degradation increases Rho-mOREG activity under
conditions that block export from ER and Golgi compart-
ments, the functionally responsive Rho-mOREG popula-
tion likely resides in an intracellular compartment.
To inhibit protein trafficking from the ER, brefeldin A
(BFA), which blocks ER export of cargo proteins by induc-
ing collapse of the Golgi stacks into the ER, was used [30].
As shown in Fig. 5A, BFA completely blocked the
enhancement of Rho-mOREG function by 3-MA and MG-
132; by contrast, BFA had no effect on functional
responses of the β-AR, indicating that BFA was not affect-
ing the function or trafficking of signal transduction
machinery, including CNG, coupled to Rho-mOREG. By
blocking transport of proteins present in the ER that are in
route to the plasma membrane, specifically Rho-mOREG
following inhibition of ER degradation, BFA inhibited
Rho-mOREG function; β-AR and CNG function were
unperturbed since these proteins were already present at
the plasma membrane prior to BFA treatment. Since β-AR
exhibits a long half-life at the plasma membrane [31],
inhibiting delivery of newly synthesized β-AR by BFA
would not adversely affect isoproterenol responses. Thus,
ER export is required for increased Rho-mOREG func-
tional expression by degradation inhibitors.
To inhibit protein trafficking from the Golgi apparatus,
monensin, an ionophore that disrupts Golgi structure and
inhibits Golgi trafficking events, was used [32]. Mon-
ensin, similar to BFA, completely blocked the enhance-
ment of Rho-mOREG function by 3-MA and MG-132
while having no effect on β-AR function (Fig. 5A). Similar
effects were observed when cells were incubated at 20°C
(Fig. 5A), a temperature that arrests protein transport at
trans Golgi cisternae [33]. Importantly, trafficking dis-
rupting agents did not affect Rho-mOREG or β-AR func-
tion when acutely applied to cells, further substantiating
that results were not attributable to non-specific effects on
signal transduction machinery or eugenol binding (Fig.
5B). Thus, Golgi trafficking events are required for
increased Rho-mOREG functional expression by degrada-
tion inhibitors.
Inhibition of Rho-mOREG function by trafficking disrupt-
ing agents, specifically BFA, could be due to activation of
the unfolded protein response [34] and inhibition of Rho-
mOREG protein synthesis. To directly address this possi-
bility, experiments were performed to test the effect of the
protein synthesis inhibitor cycloheximide (CHX) on func-
tional expression of Rho-mOREG. As shown in Figure 5C,
CHX, used at concentrations previously demonstrated to
inhibit Rho-mOREG translation [7], had no effect on
increased Rho-mOREG function by 3-MA and MG-132.
These data suggest that autophagy and ubiquitin-proteas-
ome inhibitors diverted an existing pool of Rho-mOREG
from degradative pathways to the secretory pathway and
that effects of degradation inhibitors and trafficking dis-
rupting agents were not attributable to modulation of
protein synthesis.
Collectively, these data support a model whereby inhibi-
tion of ER degradation promotes a small fraction of Rho-
mOREG to achieve an ER export competent conforma-
tion, thereby satisfying ER quality control processes, and
traffic through the secretory pathway to the plasma mem-
brane. Thus, similar to chemical and pharmacological
chaperones that promote folding and restore ER export of
misfolded GPCR cargo [35-37], agents interfering with ER
degradation may promote ER export of GPCR and non-
GPCR cargo [38], trafficking through the biosynthetic
pathway, and functional expression at the cell surface. We
speculate that the pool of Rho-mOREG expressed at the
plasma membrane is below the detection limits of cell
biological techniques used to visualize the receptor [7]
but above the detection threshold for calcium imaging
methodology used to examine receptor function. Indeed,
following pharmacological treatments, improved ∆F508
cystic fibrosis transmembrane conductance regulatorBMC Cell Biology 2004, 5:34 http://www.biomedcentral.com/1471-2121/5/34
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ER export and trafficking through the Golgi apparatus are required for Rho-mOREG functional expression Figure 5
ER export and trafficking through the Golgi apparatus are required for Rho-mOREG functional expression. 
CNG cells transiently transfected with Rho-mOREG were assayed for increases in intracellular calcium in response to 10 uM 
eugenol, to gauge Rho-mOREG function, or 1 nM isoproterenol, to gauge β-AR function, following treatment with vehicle 
(0.1% ethanol), BFA (5 ug/ml), monensin (10 uM), or incubation at 20°C for 4 h (A) or 5 min (B). (C) Cells were treated with 
vehicle or CHX (75 uM) for 4 hr. In all experiments, cells were also co-treated for 4 h with control (0.1% DMSO), 10 mM 3-
MA, or 50 uM MG-132 as indicated. Partial inhibition of Rho-mOREG function with BFA or monensin but not 20°C (A, control 
columns), a temperature that also attenuates endocytic events, is likely attributable to turnover of cell surface Rho-mOREG 
when the biosynthetic pathway, which normally replenishes the plasma membrane Rho-mOREG pool, is blocked. By contrast, 
BFA and monensin do not affect function of the β-AR, a control GPCR that exhibits a long half-life at the plasma membrane 
[31]. * p < 0.005 compared to cells treated with vehicle in the same group.BMC Cell Biology 2004, 5:34 http://www.biomedcentral.com/1471-2121/5/34
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functional expression at the plasma membrane is readily
detectable by sensitive electrophysiological analyses but
neither by cell surface labeling nor by biochemical
approaches measuring carbohydrate modifications indic-
ative of transit through the Golgi apparatus [39-41].
Though we favor a model whereby inhibition of ER deg-
radation promotes OR export from the ER and improves
OR surface expression, we were unable to obtain cellular
and biochemical evidence to support this proposal. We
cannot exclude the possibility that inhibition of ER degra-
dation also stabilizes an otherwise labile cofactor or chap-
erone protein, endogenously expressed by heterologous
cells, that modulates OR trafficking in a post-Golgi
compartment, stability at the cell surface, and/or function
at the plasma membrane [42,43].
Conclusions
We have developed an expression system for ORs that uti-
lizes signal transduction machinery coupled to OR activa-
tion in native olfactory sensory neurons. Using CNG as a
cAMP biosensor to gauge mOREG function, we demon-
strate that inhibition of ER degradation, by both
autophagy and the ubiquitin-proteasome system, pro-
motes functional expression of Rho-mOREG as well as
untagged mOREG. Thus, proteolysis limits mOREG func-
tion in heterologous cells. Inhibition of ER degradation
may improve the function of other ORs and assist future




Rho20-mOREG expression vector was generated in pRK5
as previously described [7]. To generate untagged mOREG
expression vector, mOREG coding sequence was excised
using AscI/NotI and subcloned into a modified pRK5 vec-
tor lacking the Rho20 tag. The human CNGA2 and
CNGB1b expression constructs encode untagged human
CNGA2 and CNGB1b in pEAK10-derived vectors (Edge
Biosystems, Gaithersburg, MD) [44]. For the generation of
stable transfectants, CNGA2 was subcloned into
pCDNA3.1/zeo (Invitrogen, Carlsbad, CA). The CNGA2
clone contains the C458W and E581M mutations, intro-
duced using the QuickChange Site-Directed Mutagenesis
Kit (Stratagene, La Jolla, CA), previously shown to
increase cAMP sensitivity in rat CNGA2 [11].
Compounds, odorants, and ligands
BFA, isoproterenol, monensin, and 3-MA were from
Sigma (St. Louis, MO); MG-132 was from Calbiochem
(San Diego, CA); eugenol, heptanal and octanal were
from Aldrich (Milwaukee, WI).
Cell culture and transfections
HEK293 cells were maintained and transfected as previ-
ously described [7]. For the generation of CNG stable
transfectants, cells were transfected with linearized
CNGA2 and CNGB1b expression constructs (1:1 ratio)
and selected using 50 ug/mL zeocin (Invitrogen) and 0.5
ug/mL puromycin (Calbiochem). Individual colonies
were expanded and screened for CNG expression by assay-
ing functional responses to 500 uM eugenol following
transient transfection with Rho-mOREG. For functional
expression studies, CNG cells were grown in media with-
out selection 72 h prior to experimentation and
transiently transfected with mOREG 48 h prior to
experimentation.
mOREG functional expression
Functional expression of mOREG was investigated using
calcium imaging methodology as previously described
[44]. Cells seeded in 24 well plates were loaded with the
calcium dye fluo-4 acetoxymethyl ester (Molecular
Probes, Eugene, OR) 2 d post-transfection using the fol-
lowing conditions: 3 uM dye in 0.5 ml Hanks' balanced
salt solution containing divalent cations (HBSS, Invitro-
gen) for 1 h at room temperature in the dark. Cells were
subsequently washed once with 0.5 ml HBSS to remove
excess fluo-4, supplemented with 0.25 ml HBSS, and then
stimulated with an additional 0.25 ml HBSS containing
the appropriate ligand at twice the final concentration. A
single ligand was applied to each dish of cells. Typically,
3–4 separate dishes of cells were used for each ligand con-
centration or condition and experiments were repeated 3–
4 times. Thus, individual data points represent the average
of 9–16 separate measurements.
Changes in intracellular calcium were monitored by fluo-
rescence microscopy using an Axiovert S100 TV inverted
microscope with a 10× long working distance Plan Fluor
objective (numerical aperture 0.5) and a cooled charge-
coupled device camera (Princeton Instruments, Trenton,
NJ). Images were acquired using a Lambda DG-4 auto-
mated wavelength controller (Sutter Instrument Co.,
Novato, CA) at 480 nm excitation and 535 nm emission
and analyzed using Imaging Workbench 4.0 (Axon Instru-
ments, Union City, CA). Counting the number of cells
responding to ligands 60 sec following stimulus addition,
when cells had achieved a maximal response, quantitated
receptor activity. This established methodology has been
used to functionally characterize the human T1R1/T1R3
umami receptor, the human T1R2/T1R3 sweet receptor,
and the Drosophila Gr5a trehalose receptor [44,45]. To
independently validate this method, we determined that
the EC50 for isoproterenol activation of the β-AR (3.7 +/-
1.0 nM), measured by counting responding cells, closely
matched published values (1.7–3.3 nM), measured either
by fluorescent intensity measurements or a cAMPBMC Cell Biology 2004, 5:34 http://www.biomedcentral.com/1471-2121/5/34
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accumulation assay [10]. In addition, the EC50 for eugenol
activation of Rho-mOREG (20.8 +/- 3.4 uM), measured by
counting responding cells, closely approximated the pub-
lished value (35 uM and 46 uM), determined by monitor-
ing fluorescent intensity of responding cells [8,19].
Finally, the EC50s for glutamate activation of mGluR4
and cycloheximide activation of mT2R05 were similar
when determined by counting cells or by monitoring flu-
orescent intensity [44].
We estimate ~40–50% of transfected CNG cells express
functional cell surface Rho-mOREG based on the follow-
ing points. First, ~20–25% of total cells in a microscopic
field respond to maximal doses of eugenol. Second, ~50%
of cells are transfected, measured by either co-transfection
with red fluorescent protein or by immunolabelling per-
meabilized cells expressing Rho-mOREG with an anti-
Rho antibody. Thus, ~40–50% of transfected cells express
sufficient Rho-mOREG at the plasma membrane to elicit
a functional response.
Statistics
Data represent the mean +/- SEM. Statistical significance
was determined using an unpaired, two-tailed Student's t-
test. Dose-response curves were plotted and EC50 values
were determined using GraphPad Prism v3.02 software.
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